Physician profile
Curtis Michael Keller
NPI 1295963791
$2,061.32
in general payments reported to CMS, 2019-2025
23 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2021: $24.90 · 2022: $750 · 2023: $971 · 2024: $17.75 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $552.74 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $308.04 | 2022-2023 | Nuplazid |
| Biogen, INC. | $208.50 | 2019-2025 | Vumerity, Tysabri |
| Nevro Corp. | $132.13 | 2023 | Senza |
| Sk Life Science, INC. | $111.90 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $103.67 | 2022-2023 | |
| Amgen INC. | $97.32 | 2019-2023 | Aimovig |
| Argenx US, INC. | $72.78 | 2022-2023 | Vyvgart |
| Lundbeck LLC | $59.29 | 2022-2023 | Vyepti |
| Genzyme Corporation | $49.49 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $43.03 | 2019 | |
| Mdd US Operations, LLC | $40.40 | 2019 | |
| Genentech USA, INC. | $37.97 | 2022-2023 | Ocrevus |
| Lilly USA, LLC | $37.74 | 2022-2023 | Amyvid |
| Neurelis, INC. | $35.15 | 2022-2023 | Valtoco |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $32.09 | 2019 | |
| Impel Pharmaceuticals INC. | $26.87 | 2023 | Trudhesa |
| Sunovion Pharmaceuticals INC. | $24.90 | 2021 | |
| Celgene Corporation | $19.96 | 2023 | Zeposia |
| Alexion Pharmaceuticals, INC. | $18.71 | 2023 | Ultomiris |
| Eisai INC. | $18.30 | 2023 | |
| Alnylam Pharmaceuticals INC. | $18.04 | 2023 | Amvuttra |
| Livanova USA, INC. | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.